BACKGROUND: In obese subjects with obstructive sleep apnea (OSA), chronic intermittent hypoxia (CIH) may be linked to systemic and adipose tissue inflammation. METHODS: We obtained abdominal subcutaneous adipose tissue biopsies from OSA and non-OSA obese (BMI > 35) subjects at baseline and after 24 weeks (T1) of weight-loss intervention plus continuous positive airway pressure (c-PAP) or weight-loss intervention alone, respectively. OSA subjects were grouped according to good (therapeutic) or poor (subtherapeutic) adherence to c-PAP. RESULTS: At baseline, anthropometric and metabolic parameters, serum cytokines, and adipose tissue mRNA levels of obesity-associated chemokines and inflammatory markers were not different in OSA and non-OSA subjects. At T1, body weight was significantly reduced in all groups. Serum concentrations of IL-2, IL-4, IL-6, MCP-1, PDGFβ, and VEGFα were reduced by therapeutic c-PAP in OSA subjects and remained unaltered in non-OSA and subtherapeutic c-PAP groups. Similarly, adipose tissue mRNA levels of macrophage-specific (CD68, CD36) and ER stress (ATF4, CHOP, ERO-1) gene markers, as well as of IL-6, PDGFβ, and VEGFα, were decreased only in the therapeutic c-PAP group. CONCLUSION: CIH does not represent an additional factor increasing systemic and adipose tissue inflammation in morbid obesity. However, in subjects with OSA, an effective c-PAP therapy improves systemic and obesity-associated inflammatory markers. FUNDING: Ministero dell'Università e della Ricerca and Progetti di Rilevante Interesse Nazionale.
BACKGROUND: In obese subjects with obstructive sleep apnea (OSA), chronic intermittent hypoxia (CIH) may be linked to systemic and adipose tissue inflammation. METHODS: We obtained abdominal subcutaneous adipose tissue biopsies from OSA and non-OSA obese (BMI > 35) subjects at baseline and after 24 weeks (T1) of weight-loss intervention plus continuous positive airway pressure (c-PAP) or weight-loss intervention alone, respectively. OSA subjects were grouped according to good (therapeutic) or poor (subtherapeutic) adherence to c-PAP. RESULTS: At baseline, anthropometric and metabolic parameters, serum cytokines, and adipose tissue mRNA levels of obesity-associated chemokines and inflammatory markers were not different in OSA and non-OSA subjects. At T1, body weight was significantly reduced in all groups. Serum concentrations of IL-2, IL-4, IL-6, MCP-1, PDGFβ, and VEGFα were reduced by therapeutic c-PAP in OSA subjects and remained unaltered in non-OSA and subtherapeutic c-PAP groups. Similarly, adipose tissue mRNA levels of macrophage-specific (CD68, CD36) and ER stress (ATF4, CHOP, ERO-1) gene markers, as well as of IL-6, PDGFβ, and VEGFα, were decreased only in the therapeutic c-PAP group. CONCLUSION:CIH does not represent an additional factor increasing systemic and adipose tissue inflammation in morbid obesity. However, in subjects with OSA, an effective c-PAP therapy improves systemic and obesity-associated inflammatory markers. FUNDING: Ministero dell'Università e della Ricerca and Progetti di Rilevante Interesse Nazionale.
Authors: Amy M Sawyer; Nalaka S Gooneratne; Carole L Marcus; Dafna Ofer; Kathy C Richards; Terri E Weaver Journal: Sleep Med Rev Date: 2011-06-08 Impact factor: 11.609
Authors: John B Dixon; Linda M Schachter; Paul E O'Brien; Kay Jones; Mariee Grima; Gavin Lambert; Wendy Brown; Michael Bailey; Matthew T Naughton Journal: JAMA Date: 2012-09-19 Impact factor: 56.272
Authors: Joakim Huber; Florian W Kiefer; Maximilian Zeyda; Bernhard Ludvik; Gerd R Silberhumer; Gerhard Prager; Gerhard J Zlabinger; Thomas M Stulnig Journal: J Clin Endocrinol Metab Date: 2008-05-20 Impact factor: 5.958
Authors: Clarence M Findley; Robert G Mitchell; Brian D Duscha; Brian H Annex; Christopher D Kontos Journal: J Am Coll Cardiol Date: 2008-07-29 Impact factor: 24.094
Authors: David J Kennedy; Sai Kuchibhotla; Kristen M Westfall; Roy L Silverstein; Richard E Morton; Maria Febbraio Journal: Cardiovasc Res Date: 2010-11-18 Impact factor: 10.787
Authors: S Porro; V A Genchi; A Cignarelli; A Natalicchio; L Laviola; F Giorgino; S Perrini Journal: J Endocrinol Invest Date: 2020-11-03 Impact factor: 4.256
Authors: Ewa Migacz; Wioletta Olejarz; Alicja Głuszko; Katarzyna Bednarek-Rajewska; Robert Proczka; David F Smith; Stacey L Ishman; Wojciech Kukwa Journal: Diagnostics (Basel) Date: 2021-05-22
Authors: Angelo Cignarelli; Marco Castellana; Giorgio Castellana; Sebastio Perrini; Francesco Brescia; Annalisa Natalicchio; Gabriella Garruti; Luigi Laviola; Onofrio Resta; Francesco Giorgino Journal: Front Endocrinol (Lausanne) Date: 2019-08-21 Impact factor: 5.555